New generic could put pressure on Veloxis
A generic version of the main competitor to Veloxis’ Envarsus XR will soon enter the European market and it could potentially pose a threat to the Danish biotech company’s key asset.
BY MARTIN HAVTORN PETERSEN
EMA’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of a generic version of a drug from the Japanese Astellas Pharma, and though it will mainly affect the Japanese group, it might also spell bad news for the Danish biotech company Veloxis.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Veloxis hires chief scientific officer from BMS
For abonnenter
Veloxis expands to China and Canada
For abonnenter
Veloxis CEO expects to close partnership deals this year
For abonnenter
